AuraSandbox
ScreenerSectorsLearnMethodDesign
Search companies...
CtrlK
Request access
AuraSandbox
ScreenerSectorsLearnMethodDesign
Search companies...
CtrlK
Request access
Back to screenerCompare

DIVISLAB — DIVI S LABORATORIES LTD

Price History

Data as of 26 Jun 2026· via fincrux

How DIVISLAB has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Upper end of its 12-month range81% of range

Trading about 18% above its 12-month low and near recent highs — historically pricier territory for this stock. It sits above its 200-day average, the longer-term trend.

₹5,690 low₹6,952 high
vs 50-day avg
+1.1%
vs 200-day avg
+5.5%
Beginner mode
Plain English, with everything explained

DIVISLAB

NSE

DIVI S LABORATORIES LTD

Healthcare / Pharma

₹6,713.50
0.00%
last close
0%
Quality Score
Looks high-qualityBig money steady

DIVI S LABORATORIES LTD clears 3 of 3 of our quality checks. By the numbers, it looks like a sturdy, well-run business at a fair price. Still your call — but this is the kind of company that doesn't rely on hype.

Company size
₹176218.00 Cr
Price tag
66.2×
Money it earns
16.8%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.00goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Aligned

It turns its money into healthy profits year after year. A hallmark of a quality business.

ROE 16.8%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Aligned

Professional investors have been holding steady or buying more — a quiet vote of confidence.

FII+DII 39.4%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]
Data as of 26 Jun 2026· via fincrux

Aura is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What DIVISLAB owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Mar '26
Borrowings00020
Equity Capital5353535353
Reserves11,63812,65213,43114,84216,658
Total Assets13,30814,35215,36216,82419,954
Total Liabilities13,30814,35215,36216,82419,954

Borrowings broadly stable

Total borrowings have stayed fairly level over the last 5 years.

Periodic Performance

Yearly net profit for DIVISLAB — does it earn money consistently?

Potential turnaroundPotential turnaround (pattern in the data)

Profit dipped in the middle years and has been recovering in the most recent ones. That's a pattern in the data, not a forecast.

₹2,949 Cr
₹1,808 Cr
₹1,576 Cr
₹2,209 Cr
₹2,607 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹8,880 Crrev ₹7,625 Crrev ₹7,665 Crrev ₹9,198 Crrev ₹10,388 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about DIVISLAB — observations, not recommendations.

Strengths

4
  • Turns owners' money into healthy profits, year after year.
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Large professional investors have been holding steady or adding to their stake.
  • Recent results show a return to profit after weaker years — a turnaround pattern in the data.

Risks

1
  • Sits near the top of its 12-month range — historically pricier territory for this stock.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
20.3%+0.6 pp
DII· Domestic institutions
19.1%+0.2 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Pharma score on the same four guardrails.

  • ALKEMALKEM LABORATORIES LTD.100
  • ZYDUSLIFEZYDUS LIFESCIENCES LTD100
  • IPCALABIPCA LABORATORIES LTD100
  • AJANTPHARMAJANTA PHARMA LIMITED100
  • LAURUSLABSLAURUS LABS LIMITED100
View the full sector